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Thinking Outside the “Box”—
The Ultrasound Contrast Controversy
Michael L. Main, MD, FACC,* Jonathan H. Goldman, MD, FACC,† Paul A. Grayburn, MD, FACC‡
Kansas City, Missouri; San Francisco, California; and Dallas, Texas
On October 10, 2007, the U.S. Food and Drug Administration (FDA) announced a new “black box” warning for
the perflutren-containing ultrasound contrast agents, contraindicating their use in patients with acute coronary
syndromes, acute myocardial infarction, and worsening or clinically unstable heart failure. These warnings ignore
the proven efficacy of ultrasound contrast agents, the previously established safety of these compounds, the
potential risks of alternative procedures, and the likely confounding effect of pseudocomplication. We suggest
that the FDA Medical Imaging Division convene a panel of cardiologists experienced in a variety of imaging mo-
dalities to fully assess the adverse events that have been attributed to these agents and that any future FDA
warnings acknowledge the possible influence of pseudocomplication, the proven efficacy of the modality in
question for early and accurate diagnosis of cardiovascular disease, and the known and theoretical risks of alter-
native testing that may be necessary. (J Am Coll Cardiol 2007;50:2434–7) © 2007 by the American College of
Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.11.006t
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wn October 10, 2007, the U.S. Food and Drug Adminis-
ration (FDA) announced a new “black box” warning for the
erflutren-containing ultrasound contrast agents, contrain-
icating their use in patients with acute coronary syn-
romes, acute myocardial infarction, and worsening or
linically unstable heart failure (1). These warnings followed
ost-marketing reports of 4 patient deaths, which were
emporally related, but not clearly causally attributable to,
ontrast injection. Although appearing prudent at face
alue, especially in light of the recent intense focus on
atient safety, these strident warnings ignore the proven
fficacy of ultrasound contrast agents, the previously estab-
ished safety of these compounds, the potential risks of
lternative procedures, and the likely confounding effect of
seudocomplication. To fully appreciate all this, some
ackground is necessary.
Despite significant advances in ultrasound transducer
esign and signal processing technology (2), as many as 20%
f echocardiographic examinations remain technically diffi-
ult, largely because of patient factors such as the existence
f lung disease and obesity (3). In an effort to circumvent
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007, accepted November 13, 2007.his problem, researchers developed ultrasound contrast
gents (“microbubbles”) that were capable of transpulmo-
ary passage after intravenous injection. In 1994, the first
ltrasound contrast agent (Albunex® [MBI, San Diego,
alifornia], air-filled sonicated albumin microbubbles) was
pproved for human use in the U.S. (4–6). More recently,
second-generation” fluorocarbon-based agents Optison™
GE Healthcare, Buckinghamshire, United Kingdom) (7)
nd Definity® (Bristol-Myers Squibb Medical Imaging,
illerica, Massachusetts) (8) were approved by the FDA
fter demonstrating superiority to Albunex® and placebo,
espectively. Although Optison™ has not been marketed
ince 2005, Definity® is in widespread clinical use today,
ith $65 million in sales in 2006, and approximately 2
illion patients dosed since product approval in 2001.
Significant safety data exist for these compounds. Dose-
anging studies have shown no changes in systemic or
ulmonary hemodynamics, myocardial contractility, gas ex-
hange, or regional myocardial blood flow even after 30
njections over the course of 10 min at doses capable of
roviding myocardial opacification (9). Large-scale Phase
II studies of more than 1,700 patients leading to product
pproval revealed no safety concerns (7,8). Additionally,
here is no defined mechanism for a toxic relationship.
hese agents act as true red blood cell flow tracers in the
ystemic circulation after intravenous injection (10) and,
nlike the nuclear isotopes used in scintigraphic studies, do
ot require (or undergo) cellular uptake or mitochondrial
etabolism; the fluorocarbon gas is excreted by the lungs
ithin minutes. Additional characteristics contribute toheir utility as echocardiographic contrast agents and
l
m
b
b
a
c
q
i
n
r
a
u
m
i
p
f
d
m
e
r
c
t
e
r
t
t
P
i
t
b
T
i
(
m
i
c
n
o
p
d
i
t
a
c
i
t
s
r
o
a
(
e
a
s
4
s
c
r
t
c
g
o
h
e
f
h
A
c
w
i
c
m
i
a
t
v
r
a
p
1
t
p
p
n
o
t
f
p
i
l
w
b
b
a
fi
p
t
r
n
d
n
t
t
v
m
f
2435JACC Vol. 50, No. 25, 2007 Main et al.
December 18/25, 2007:2434–7 Ultrasound Contrast Controversyimit the potential for bioeffects. Because of their high
olecular weight, the fluorocarbon gases are insoluble in
lood and do not readily diffuse across microbubble mem-
ranes (11,12). Additionally, because carbon-fluorine bonds
re the tightest covalent bonds found in nature, perfluoro-
arbons are biologically inert.
The efficacy of echocardiographic contrast agents is not in
uestion—multiple studies have established their utility in
mproving accuracy of stress echocardiography for the diag-
osis of obstructive coronary artery disease (13–15) and in
educing health care costs by eliminating the need for
dditional testing (16). Contrast agents may be even more
seful in nonstress studies. With candidacy for drug and
edical device therapy in patients with acute myocardial
nfarction and heart failure now increasingly determined by
hysicians with the use of left ventricular (LV) ejection
raction partition values (17,18), accurate and reproducible
etermination of LV size and systolic function is para-
ount. Contrast administration improves the agreement of
chocardiographically determined LV ejection fraction with
eference techniques such as cardiac magnetic resonance and
omputed tomographic imaging (19–21), and reduces in-
erobserver variability, even in patients with good baseline
ndocardial border delineation (22).
It is important to realize that complications occur-
ing after any medical procedure may be attributable to
he procedure itself or may be due to progression of
he underlying disease state (“pseudocomplication”).
seudocomplication was well defined for cardiac catheter-
zation by Hildner et al. decades ago (23,24). These inves-
igators examined “complications” that occurred from 24 h
efore to 72 h after a scheduled cardiac catheterization.
hey found an event rate of 0.81% (with 0.24% mortality)
n the day before the procedure and an event rate of 0.81%
with no deaths) in the post-procedural interval. Thus,
ajor cardiac events, including death, are relatively common
n patients who are “sick enough” to warrant invasive
ardiovascular testing. To our knowledge, such a study has
ever been performed in patients scheduled for echocardi-
graphy. What we do know is that echocardiography is the
rocedure of choice (and often the only diagnostic proce-
ure possible) in critically ill patients; common inpatient
ndications for echocardiographic evaluation include “hypo-
ension,” “shock,” “status post cardiac arrest,” and “tampon-
de.” It is important to differentiate between association and
ausation; without knowledge of the ambient event rate, any
ncremental risk of contrast agents (or any other interven-
ion) cannot be known.
A review of the 4 cases in which patients died during or
hortly after Definity® administration supports the possible
ole of pseudocomplication (1). Patient #1 was a 67-year-
ld man with an ischemic cardiomyopathy who experienced
cardiac arrest 1 min after beginning an exercise stress test
and 30 min after receiving Definity®). Patient #2 was an
lderly man hospitalized in a cardiac intensive care unit withrecent myocardial infarction and severely reduced LV tystolic function. Approximately
h after admission to the inten-
ive care unit, he underwent
ontrast-enhanced echocardiog-
aphy after first receiving a seda-
ive for agitation. Shortly after
ompletion of the echocardio-
ram, he suffered cardiac arrest. Patient #3 was a 70-year-
ld man with a history of coronary artery bypass grafting,
eart failure, and deep venous thrombosis. He underwent
chocardiography with contrast to evaluate worsening heart
ailure. Approximately 5 min after completion of the study,
e became cyanotic and hypotensive and subsequently died.
massive pulmonary embolism was reported as the likely
ause of death. Patient #4 was a 34-year-old morbidly obese
oman (body weight 350 lbs) who was admitted to an
ntensive care unit for severe trilobar pneumonia. Her
oncomitant medical problems included postpartum cardio-
yopathy. She required mechanical ventilation and multiple
ntravenous vasopressor agents. She arrested immediately
fter the injection of Definity®. A post-mortem examina-
ion revealed multiple pulmonary emboli and a large right
entricular thrombus.
Even if all of the reported events occurred as a direct
esult of contrast administration (which is unlikely, because
significant proportion must be attributable to pseudocom-
lication), this result would still indicate an approximate
:500,000 risk of death based on events acknowledged by
he FDA and manufacturer data on total patient doses since
roduct approval. It is important to put this number in
roper perspective. The mortality rate for diagnostic coro-
ary angiography is approximately 1:1,000 (25), and the risk
f myocardial infarction or death with exercise treadmill
esting is approximately 1:2,500 (26). The lifetime risk of
atal malignancy after stress single-photon emission com-
uted tomography or radionuclide ventriculogram exam-
nation is estimated at 1:1,000 to 1:10,000 (27,28). This
atter risk is greatest in relatively young patients and in
omen but is generally ignored in the U.S. in part
ecause of physician and patient ignorance regarding the
iologic effects of ionizing radiation, but it also may be
ttributable to the lack of immediate risk. Despite these
nite risks of serious complication, coronary angiogra-
hy, exercise testing, and nuclear scintigraphic examina-
ions are performed without trepidation, and with good
eason—all allow early diagnosis and treatment of coro-
ary artery disease, which remains the primary cause of
eath in the U.S.
What alternatives are available in patients with nondiag-
ostic transthoracic echocardiograms and concomitant ul-
rasound contrast agent contraindications? When LV sys-
olic function is the principal clinical question, radionuclide
entriculography may be performed. This test is used in
any centers for serial evaluation of LV size and systolic
unction in oncology patients receiving potentially cardio-
Abbreviations
and Acronyms
FDA  Food and Drug
Administration
LV  left ventricularoxic chemotherapeutic regimens. Given the significant risk
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eightened with repetitive studies, this alternative would
eem to be a poor one. Additionally, nuclear testing is very
ifficult to perform at the bedside or in the critically ill. In
ost patients, transesophageal echocardiography will be the
rocedure of choice. Although a “minimally invasive” ex-
mination, serious complications, including laryngospasm
0.14%), hypotension (0.3%), hypoxia (0.3%), and death
0.01%), have been reported in a large series of patients (29).
dditionally, the risk of esophageal perforation is 0.02%
ith flexible upper endoscopy (30). The risk of perforation
ith transesophageal echocardiography is likely significantly
reater given the lack of direct visualization during intuba-
ion. Finally, methemoglobinemia occurring as the result of
he application of topical lidocaine or benzocaine is increas-
ngly being reported (31).
What will likely occur as a result of this latest FDA
arning? If previous experience is any predictor, significant
nxiety will be generated for both patients and health care
roviders. Perhaps personal injury lawyers will begin adver-
ising for “injured” clients. In fact, even the requirement to
onitor blood pressure and the electrocardiogram for 30
in after the procedure will have a chilling effect upon the
se of contrast agents. Echocardiography laboratories are
rganized for rapid patient throughput for cost effectiveness
nd do not typically have facilities or personnel for pro-
onged monitoring of ambulatory patients. Given the ab-
ence of reported severe events and the safety record in
mbulatory patients, the necessity and efficacy of such
onitoring is surely questionable. Ultrasound contrast sales
ill certainly languish, likely forcing existing agents off the
arket, and discouraging future investment and innovation
n new drug development.
What is our suggestion for resolving the controversy
urrounding this decision? First, we believe the FDA
edical Imaging Division should convene a panel of
ardiologists with and without experience in imaging mo-
alities, including echocardiography, to fully assess the
dverse events that have been attributed to Definity® and
etermine the most appropriate corrective action. At
resent, the Medical Imaging Division resides in the Office
f Oncology Drug Products and may benefit from cardiol-
gy or cardiac imaging expertise in fully evaluating this
ssue. Medical imaging is the largest single contributor to
edicare costs; it would seem appropriate that evaluators
ith true cardiac imaging expertise help adjudicate the
afety and efficacy of these modalities. Second, we rec-
mmend that any future FDA warnings acknowledge the
ossible influence of pseudocomplication, the proven
fficacy of the modality in question for accurate diagnosis
f cardiovascular disease, and the known and theoretical
isks of alternative testing that may be necessary. Only
hen will physicians and patients possess the facts to make
nformed and rational choices in the selection of diagnostic
ests.eprint requests and correspondence: Dr. Michael L. Main,
ardiovascular Consultants, 4330 Wornall Road, Suite 2000,
ansas City, Missouri 64111. E-mail: mmain@cc-pc.com.
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